HIGHLIGHTS
SUMMARY
Global reports indicate that gastric cancer (GC) is the fifth most common malignancy and the fourth leading cause of cancer death. Tumor cells can express programmed death ligand-1 (PDL1) that binds and activates PD1 in T-cells. Upon binding, activated PD1 causes T-cell "exhaustion", a process that impairs the antitumoral activity of T-cells and favors tumor progression. The use of nivolumab prevents PDL1-PD1 binding and increases antitumoral T-cell activity, which launches an immune attack on cancer cells. Essential cell signaling pathways associated with immunotherapy resistance in GC include the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.